A randomised placebo-controlled trial of prolonged prednisolone administration to patients with HELLP syndrome remote from term

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 128, Issue 1-2, 2006, Pages 187-193

  van Runnard Heimel, Pieter J ^a   Huisjes, Anjoke J M ^b   Franx, Arie ^a,c   Koopman, Corine ^a   Bots, Michiel L ^a   Bruinse, Hein W ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b GELRE HOSPITALS   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Corticosteroids; Expectant management; HELLP syndrome; RCT

Indexed keywords

PLACEBO; PREDNISOLONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DISSEMINATED INTRAVASCULAR CLOTTING; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ECLAMPSIA; FEMALE; FETUS DEATH; FOLLICULITIS; GESTATION PERIOD; HELLP SYNDROME; HUMAN; INTRAUTERINE GROWTH RETARDATION; LEUKOMALACIA; LIVER HEMATOMA; LIVER HEMORRHAGE; LIVER RUPTURE; LUNG DYSPLASIA; MATERNAL MORBIDITY; MATERNAL MORTALITY; MULTIPLE ORGAN FAILURE; OUTCOME ASSESSMENT; PERINATAL DEATH; PITYROSPORUM; PLACENTA INSUFFICIENCY; PREGNANCY; PREGNANCY COMPLICATION; PREMATURITY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK ASSESSMENT; SEPSIS; SOLUTIO PLACENTAE; THROMBOCYTE COUNT;

EID: 33747873256     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejogrb.2005.11.041     Document Type: Article

References (29)

1. Sibai B.M., Ramadan M.K., Usta I., Salama M., Mercer B.M., and Friedman S.A. Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome). Am J Obstet Gynecol 169 4 (1993) 1000-1006
2. Royal College of Obstetricians and Gynecologists. Why mothers die 1997-1999. The Fifth Report of the Confidential Enquiry into Maternal Deaths in the United Kingdom (2001), RCOG Press, London
3. Odendaal H.J., Pattinson R.C., Bam R., Grove D., and Kotze T.J. Aggressive or expectant management for patients with severe preeclampsia between 28-34 weeks' gestation: a randomized controlled trial. Obstet Gynecol 76 6 (1990) 1070-1075
4. Sibai B.M., Mercer B.M., Schiff E., and Friedman S.A. Aggressive versus expectant management of severe preeclampsia at 28-32 weeks' gestation: a randomized controlled trial. Am J Obstet Gynecol 171 3 (1994) 818-822
5. Haddad B., Deis S., Goffinet F., Paniel B.J., Cabrol D., and Siba B.M. Maternal and perinatal outcomes during expectant management of 239 severe preeclamptic women between 24 and 33 weeks' gestation. Am J Obstet Gynecol (2004) 1590-1595 (discussion 1595-1597)
6. Visser W., and Wallenburg H.C. Temporising management of severe pre-eclampsia with and without the HELLP syndrome. Br J Obstet Gynaecol 102 2 (1995) 111-117
7. van Pampus M.G., Wolf H., Westenberg S.M., van der Post J.A., Bonsel G.J., and Treffers P.E. Maternal and perinatal outcome after expectant management of the HELLP syndrome compared with pre-eclampsia without HELLP syndrome. Eur J Obstet Gynecol Reprod Biol 76 1 (1998) 31-36
8. Abramovici D., Friedman S.A., Mercer B.M., Audibert F., Kao L., and Sibai B.M. Neonatal outcome in severe preeclampsia at 24-36 weeks' gestation: does the HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome matter?. Am J Obstet Gynecol 180 1 Pt 1 (1999) 221-225
9. van Pampus M.G., Wolf H., Westenberg S.M., van der Post J.A., Bonsel G.J., and Treffers P.E. Maternal and perinatal outcome after expectant management of the HELLP syndrome compared with pre-eclampsia without HELLP syndrome. Eur J Obstet Gynecol Reprod Biol (1998) 31-36
10. Martin Jr. J.N., Blake P.G., Perry Jr. K.G., McCaul J.F., Hess L.W., and Martin R.W. The natural history of HELLP syndrome: patterns of disease progression and regression. Am J Obstet Gynecol 164 6 Pt 1 (1991) 1500-1509 (discussion 1509-1513)
11. Martin Jr. J.N., Thigpen B.D., Rose C.H., Cushman J., Moore A., and May W.L. Maternal benefit of high-dose intravenous corticosteroid therapy for HELLP syndrome. Am J Obstet Gynecol 189 3 (2003) 830-834
12. Rose C.H., Thigpen B.D., Bofill J.A., Cushman J., May W.L., and Martin Jr. J.N. Obstetric implications of antepartum corticosteroid therapy for HELLP syndrome. Obstet Gynecol 104 5 (2004) 1011-1014
13. Matchaba P., and Moodley J. Corticosteroids for HELLP syndrome in pregnancy. Cochrane Database Syst Rev 1 (2004) (CD002076)
14. Sibai B.M. Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Obstet Gynecol 103 5 Pt 1 (2004) 981-991
15. Clenney T.L., and Viera A.J. Corticosteroids for HELLP (haemolysis, elevated liver enzymes, low platelets) syndrome. BMJ (2004) 270-272
16. Magann E.F., Bass D., Chauhan S.P., Sullivan D.L., Martin R.W., and Martin Jr. J.N. Antepartum corticosteroids: disease stabilization in patients with the syndrome of hemolysis, elevated liver enzymes, and low platelets (HELLP). Am J Obstet Gynecol 171 4 (1994) 1148-1153
17. Beitins I.Z., Bayard F., Ances I.G., Kowarski A., and Migeon C.J. The transplacental passage of prednisone and prednisolone in pregnancy near term. J Pediatr 81 5 (1972) 936-945
18. Blanford A.T., and Murphy B.E. In vitro metabolism of prednisolone, dexamethasone, betamethasone, and cortisol by the human placenta. Am J Obstet Gynecol 127 3 (1977) 264-267
19. Schlembach D., Munz W., and Fischer T. Effect of corticosteroids on HELLP syndrome: a case report. J Perinat Med 28 6 (2000) 502-505
20. Sibai B.M. The HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets): much ado about nothing?. Am J Obstet Gynecol 162 2 (1990) 311-316
21. Girling J.C., Dow E., and Smith J.H. Liver function tests in pre-eclampsia: importance of comparison with a reference range derived for normal pregnancy. Br J Obstet Gynaecol (1997) 246-250
22. Giedion A., Haefliger H., and Dangel P. Acute pulmonary X-ray changes in hyaline membrane disease treated with artificial ventilation and positive end-expiratory pressure (PEP). Pediatr Radiol (1973) 145-152
23. Papile L.A., Burstein J., Burstein R., and Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights <1500 g. J Pediatr 92 4 (1978) 529-534
24. Griffiths R. The Abilities of Young Children: A Comprehensive System of Mental Measurement for the First 8 Years of Life (1970), Child Development Research Centre, London, United Kingdom
25. Bayley N. Bayley Scales of Infant Development-II (1993), Psychological Corporation, San Antonio, TX
26. van Runnard Heimel P.J., Franx A., Schobben A.F., Huisjes A.J., Derks J.B., and Bruinse H.W. Corticosteroids, pregnancy, and HELLP syndrome: a review. Obstet Gynecol Surv 60 1 (2005) 57-70
27. Jarvelainen H., Pelliniemi T.T., and Ronnemaa T. The stabilizing effect of glucocorticoids on human endothelial cells in culture. Scand J Clin Lab Invest 45 3 (1985) 223-228
28. Schleimer R.P. An overview of glucocorticoid anti-inflammatory actions. Eur J Clin Pharmacol 45 Suppl. 1 (1993) S3-S7 (discussion S43-S44)
29. Jorgensen K.A., and Stoffersen E. Hydrocortisone, platelet aggregation and platelet prostaglandin metabolism. Scand J Haematol (1980) 445-447